DJIA 17,550.69 -47.51 -0.27%
NASDAQ 5,105.55 -9.84 -0.19%
S&P 500 2,093.32 -4.72 -0.22%
market minute promo

8.09 0.03 (0.37%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ARIA $8.09 0.37%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $8.15
Previous Close $8.06
Daily Range $7.97 - $8.18
52-Week Range $4.90 - $9.89
Market Cap $1.5B
P/E Ratio -9.16
Dividend (Yield) $0.00 (0.0%)
Volume 4,454,292
Average Daily Volume 3,030,838
Current FY EPS -$1.12




Drug Makers

Ariad Pharmaceuticals, Inc. (ARIA) Description

The Company is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. Website:

News & Commentary

Is Ariad Pharmaceuticals a Cheap Stock?

Ariad Pharmaceuticals sales are climbing, but its shares may not be a bargain.

Will ARIAD (ARIA) Disappoint Estimates this Earnings Season? - Analyst Blog

Who Really Won in the PDL and Ariad Royalty Deal?

ARIAD Pharmaceuticals (ARIA) Flagged As Strong On High Volume

ARIA Crosses Below Key Moving Average Level

Premarket Biotech Digest: Options Trading, Achillion Short Interest, Opdivo EU Approval

$1.5B Ariad Is Smaller But Similar To Pharmacyclics Before The $20B Buyout

ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog

JMP Sees A 'Negative Market Tone' In Biotechnology

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

See More ARIA News...

ARIA's Top Competitors

ARIA $8.09 (0.37%)
Current stock: ARIA
AMGN $174.80 (-0.45%)
Current stock: AMGN
GILD $118.87 (-0.61%)
Current stock: GILD
BIIB $330.38 (1.85%)
Current stock: BIIB